Close Menu

SBIR grant

Empire Genomics has discovered a genetic mutation that early studies suggest might be linked to increased response to a class of drugs called proteasome inhibitors.

NEW YORK (GenomeWeb News) – Empire Genomics today announced it has received a Phase I SBIR grant from the National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma.

NEW YORK (GenomeWeb News) – TriLink BioTechnologies today announced a $130,000 award from the National Institutes of Health to develop a sample preparation method for next-generation sequencing.

NEW YORK (GenomeWeb News) – Epic Sciences today said that it has received a Phase II Small Business Innovation Research award from the National Cancer Institute and the National Institutes of Health to develop a lung cancer assay.

NEW YORK (GenomeWeb News) – Multiplex assay development firm Genalyte today announced it has been awarded a $500,000 Small Business Innovation Research grant to develop multiplexed diagnostic assays for the early detection and monitoring of type 1 diabetes.

NEW YORK (GenomeWeb News) – MicroRNA test development firm Circulomics said today it has been awarded two National Institutes of Health grants totaling $800,000 to develop its technology.

NEW YORK (GenomeWeb News) – Molecular diagnostics company Insight Genetics said on Monday it has been awarded two SBIR contracts from the National Cancer Institute to develop companion diagnostic tests aimed at lung cancer.

NEW YORK (GenomeWeb News) – New England Biolabs announced Thursday that it has received a $640,000 Phase II Small Business Innovation grant from the National Institutes of Health to expand its research into development of enzymatic tools for epigenetic analysis.

NEW YORK (GenomeWeb News) – Wake Forest University and spin-out company NanoMedica have received $860,000 in funding to move a bead-based genetic sequencing drug discovery technology closer to commercialization, Wake Forest said today.

NEW YORK (GenomeWeb News) – Mediomics has reeled in a $997,251 grant from the National Cancer Institute to continue developing technologies for monitoring the titer and quality of recombinant biologics, the company said today.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.